Is MLYS a Buy or a Sell? The Bull and Bear Case (2026)
Last updated October 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Mineralys Therapeutics (MLYS) rests on Lorundrostat FDA decision: The single largest driver is the FDA review of lorundrostat for hypertension in combination with other antihypertensives, with a PDUFA target date of December 22, 2026. The bear case rests on the dominant risk is single-asset concentration: essentially the entire thesis depends on lorundrostat, so an FDA complete response letter, label restrictions, or safety concerns would be severe. Analysts covering it publish targets from $29.00 to $56.00 against a $20.30 price, so even the professionals disagree by 58% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Mineralys Therapeutics (Nasdaq: MLYS), headquartered in Radnor, Pennsylvania, is a clinical-stage biopharmaceutical company focused on hypertension and related conditions driven by dysregulated aldosterone. Its lead and essentially only asset is lorundrostat, an orally administered, highly selective aldosterone synthase inhibitor being developed for uncontrolled and resistant hypertension, with additional programs exploring chronic kidney disease (CKD) and obstructive sleep apnea (OSA). The company completed its Phase 3 program (including the Launch-HTN and Advance-HTN trials) and submitted a New Drug Application that the FDA accepted, with a PDUFA target action date of December 22, 2026. As of its August update, commercial leadership was in place, initial sales territories had been identified, and the company expected its sales force to be built before that date. The investment picture is that of a classic binary biotech. As a pre-revenue company, Mineralys reported a net loss of about $241 million in Q2 2026, mostly a one-time $200 million payment to Tanabe Pharma that eliminated future royalties on lorundrostat (up to $255 million of commercial milestones remain). In the same quarter it raised about $150 million in a follow-on offering and drew $100 million of a term loan facility of up to $500 million from Pharmakon. Cash and investments stood at about $661 million on June 30, 2026, which management expects to fund operations, including the launch, into 2028. The stock, valued near $1.8 billion in October 2026 after a roughly 42% slide this year, still prices in a meaningful probability of approval and commercial success in a very large hypertension market. The flip side is concentration risk: a negative FDA decision, a competitive setback, or a disappointing launch would weigh heavily because there is no diversified pipeline or product revenue to cushion it.
The bull case: what would have to be true for $56.00
The most optimistic published target on MLYS is $56.00, +175.9% from the $20.30 price as of October 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Lorundrostat FDA decision
The single largest driver is the FDA review of lorundrostat for hypertension in combination with other antihypertensives, with a PDUFA target date of December 22, 2026. An approval would move Mineralys from clinical-stage to a commercial-stage company with a first-in-class-tier aldosterone synthase inhibitor. The decision is the defining catalyst for the stock, now about two months out.
2. Large uncontrolled-hypertension market
Uncontrolled and resistant hypertension affects a very large patient population that remains poorly served by existing generic therapies. Lorundrostat targets aldosterone, a hormone implicated in blood pressure that current standard regimens do not directly address. Consensus models about $88 million of revenue in 2027, the first full year after a potential approval. With the Tanabe royalty gone, more of each sales dollar would stay with Mineralys.
3. Pipeline expansion into CKD and OSA
Beyond core hypertension, Mineralys is studying lorundrostat in chronic kidney disease and obstructive sleep apnea, conditions where aldosterone dysregulation plays a role. In October 2026 it presented new data at the American Heart Association Hypertension Scientific Sessions and announced presentations at the American Society of Nephrology Kidney Week, and long-term Transform-HTN open-label extension data were picked as a late-breaker at the AHA Scientific Sessions in November.
4. Balance sheet and launch readiness
With about $661 million in cash and investments at June 30, 2026 and runway guided into 2028, Mineralys has capital to fund a launch without immediate financing pressure. That cushion came partly from a June 2026 equity raise of about $150 million (dilutive to holders) and a $100 million loan draw, with up to $400 million more available under the Pharmakon facility. A new Chief Medical Officer, Dr. Terry Ferguson (ex-Amgen, AstraZeneca), joined in August.
The bear case: what would have to be true for $29.00
The most pessimistic published target is $29.00, +42.9% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Mineralys Therapeutics is worth if the risks below bite instead of the drivers above.
The dominant risk is single-asset concentration: essentially the entire thesis depends on lorundrostat, so an FDA complete response letter, label restrictions, or safety concerns would be severe. Competition is real, most notably AstraZeneca's baxdrostat, another late-stage aldosterone synthase inhibitor with strong Phase 3 data, plus other emerging candidates. As a pre-revenue biotech, Mineralys burns cash, has raised equity, and now carries about $98 million of debt, creating dilution and leverage risk. Even with approval, commercial execution (payer coverage, physician adoption, and pricing in a market full of cheap generics) is uncertain. The stock is volatile and highly sensitive to regulatory news: it fell about 26% in the month to October 16, 2026 and closed near its 52-week low of about $20.41, against a high of about $47.65.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding MLYS already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on MLYS
9 analysts cover MLYS, with an average target of $46.33 (+128.2% against $20.30) and a split of 9 buy, 2 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the MLYS forecast and price target page.
How is MLYS valued? (as of October 2026)
Snapshot for MLYS as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Product revenue (TTM): ~$0 (pre-commercial)
- Cash & investments: ~$661M (June 30, 2026); runway guided into 2028
- Q2 2026 net loss: ~$241M, incl. $200M one-time Tanabe royalty buyout
- Q2 2026 R&D expense: ~$221M (about $21M excluding the Tanabe payment)
- Net loss (TTM): ~$350M; EPS about -$4.22
- Debt: ~$98M (Pharmakon term loan, up to $500M facility)
- Market cap: ~$1.8B (share price ~$20.83)
Standard valuation multiples do not apply to Mineralys because it has no product revenue and posts ongoing losses funded by its cash balance. The roughly $1.8 billion market value, about 2.8 times its cash, reflects the market's probability-weighted view of lorundrostat's approval and future sales, not trailing fundamentals. The nine covering analysts rate it a strong buy with a mean target near $46, more than double the current price, a gap that shows how much rides on the December 22 decision.
How do you decide if MLYS is a buy?
Rather than asking whether MLYS is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold MLYS indirectly through an index or sector ETF before adding more.
What would change your mind on MLYS
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Lorundrostat FDA decision stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: the dominant risk is single-asset concentration: essentially the entire thesis depends on lorundrostat, so an FDA complete response letter, label restrictions, or safety concerns would be severe fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the MLYS stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about MLYS against your real portfolio and see your actual exposure before deciding.
Investing in Mineralys Therapeutics with AI
Connect the broker you already use and ask Walnut's AI how MLYS fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is MLYS a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Lorundrostat FDA decision, with product revenue (ttm) at ~$0 (pre-commercial). The bear case rests on the dominant risk is single-asset concentration: essentially the entire thesis depends on lorundrostat, so an FDA complete response letter, label restrictions, or safety concerns would be severe. Analysts covering it are spread from $29.00 to $56.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell MLYS?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The dominant risk is single-asset concentration: essentially the entire thesis depends on lorundrostat, so an FDA complete response letter, label restrictions, or safety concerns would be severe. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $29.00, +42.9% from the $20.30 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for MLYS?
+
Lorundrostat FDA decision. The single largest driver is the FDA review of lorundrostat for hypertension in combination with other antihypertensives, with a PDUFA target date of December 22, 2026. The most optimistic analyst target on MLYS is $56.00, +175.9% from the $20.30 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for MLYS?
+
The dominant risk is single-asset concentration: essentially the entire thesis depends on lorundrostat, so an FDA complete response letter, label restrictions, or safety concerns would be severe. Competition is real, most notably AstraZeneca's baxdrostat, another late-stage aldosterone synthase inhibitor with strong Phase 3 data, plus other emerging candidates. As a pre-revenue biotech, Mineralys burns cash, has raised equity, and now carries about $98 million of debt, creating dilution and leverage risk. Even with approval, commercial execution (payer coverage, physician adoption, and pricing in a market full of cheap generics) is uncertain. The stock is volatile and highly sensitive to regulatory news: it fell about 26% in the month to October 16, 2026 and closed near its 52-week low of about $20.41, against a high of about $47.65. The most pessimistic published target is $29.00, +42.9% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Mineralys Therapeutics do?
+
Mineralys Therapeutics (Nasdaq: MLYS), headquartered in Radnor, Pennsylvania, is a clinical-stage biopharmaceutical company focused on hypertension and related conditions driven by
What would have to change for MLYS to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Lorundrostat FDA decision) stalling in the reported numbers rather than in the narrative, the risk above (the dominant risk is single-asset concentration: essentially the entire thesis depends on lorundrostat, so an FDA complete response letter, label restrictions, or safety concerns would be severe) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Mineralys Therapeutics (MLYS) do?
+
Mineralys is a clinical-stage biopharmaceutical company developing lorundrostat, an oral aldosterone synthase inhibitor for uncontrolled and resistant hypertension, with additional research in chronic kidney disease and obstructive sleep apnea. It is based in Radnor, Pennsylvania, and had 76 employees as it built out a sales organization ahead of a potential approval.
Does MLYS have any approved products or revenue?
+
No. As of October 2026 Mineralys has no approved products and no product revenue. It is pre-commercial, funding operations from its cash balance while its lead drug lorundrostat is under FDA review. Analysts expect the first sales in 2027 if the drug is approved.
What is the FDA decision date for lorundrostat?
+
The FDA accepted the lorundrostat New Drug Application and set a PDUFA target action date of December 22, 2026. That decision is the single most important near-term event for the company and the stock. The company said in August that the review was continuing and launch preparations were on track.
Walnut is informational, not investment advice, and gives no verdict on MLYS. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.